Information Provided By:
Fly News Breaks for March 3, 2016
BMRN
Mar 3, 2016 | 05:57 EDT
Piper Jaffray analyst Joshua Schimmer views the data BioMarin announced last night for the treatment of CLN2 disease, a form of Batten disease, as promising. If these early results hold up over time, Cerliponase alfa's peak sales could top $500M, Schimmer tells investors in a research note. "It's nice to see the sector stringing together some positive news after numerous disappointments," the analyst writes. He reiterates an Overweight rating on BioMarin with a $107 price target.
News For BMRN From the Last 2 Days
There are no results for your query BMRN